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Abstract
Introduction: Our aim was to evaluate the role of B-type natriuretic peptide (BNP) percentage variations at 24 hours 
and at discharge compared to its value at admission in order to demonstrate its predictive value for outcomes in 
patients with acute decompensated heart failure (ADHF).
Methods: This was a multicenter Italian (8 centers) observational study (Italian Research Emergency Department: RED). 
287 patients with ADHF were studied through physical exams, lab tests, chest X Ray, electrocardiograms (ECGs) and 
BNP measurements, performed at admission, at 24 hours, and at discharge. Follow up was performed 180 days after 
hospital discharge. Logistic regression analysis was used to estimate odds ratios (OR) for the various subgroups created. 
For all comparisons, a P value < 0.05 was considered statistically significant.
Results: BNP median (interquartile range (IQR)) value at admission was 822 (412 - 1390) pg\mL; at 24 hours was 593 
(270 - 1953) and at discharge was 325 (160 - 725). A BNP reduction of >46% at discharge had an area under curve (AUC) 
of 0.70 (P < 0.001) for predicting future adverse events. There were 78 events through follow up and in 58 of these 
patients the BNP level at discharge was >300 pg/mL. A BNP reduction of 25.9% after 24 hours had an AUC at ROC curve 
of 0.64 for predicting adverse events (P < 0.001). The odds ratio of the patients whose BNP level at discharge was <300 
pg/mL and whose percentage decrease at discharge was <46% compared to the group whose BNP level at discharge 
was <300 pg/mL and whose percentage decrease at discharge was >46% was 4.775 (95% confidence interval (CI) 1.76 
- 12.83, P < 0.002). The odds ratio of the patients whose BNP level at discharge was >300 pg/mL and whose percentage 
decrease at discharge was <46% compared to the group whose BNP level at discharge was <300 pg/mL and whose 
percentage decrease at discharge was >46% was 9.614 (CI 4.51 - 20.47, P < 0.001).
Conclusions: A reduction of BNP >46% at hospital discharge compared to the admission levels coupled with a BNP 
absolute value < 300 pg/mL seems to be a very powerful negative prognostic value for future cardiovascular outcomes 
in patients hospitalized with ADHF.
Introduction
Heart failure (HF) represents an emerging and growing
public health problem [1]. In Europe, patients with a
diagnosis of chronic HF represent about 14 million peo-
ple. The prevalence is 2 to 5% in patients over the age of
65 years, with HF complications above 300,000 per year.
It is a frequent cause of adult hospitalization, especially in
elderly patients [2-4] and carries a high mortality rate [5].
Acute HF is defined as a rapid onset of signs (tachycardia,
tachypnoea, pulmonary rales, pleural effusion, raised jug-
ular venous pressure, peripheral edema, hepatomegaly)
and symptoms (breathlessness at rest or on exercise,
fatigue, tiredness, ankle swelling) of HF, resulting in the
need for urgent therapy. It could present as a new HF or
worsening HF in the presence of chronic HF [6].
Although patients appear to be effectively treated during
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their hospital stay, HF patients often experience relapses
of acute decompensation and subsequent re-hospitaliza-
tion [7]. Recent data have shown that precipitating
comorbid factors (e.g., respiratory tract infections,
arrhythmias, cardiac ischemia) were associated with
more severe clinical outcomes independent of other
prognostic factors such as kidney failure or hypertension
[8]. The best current understanding suggests that in the
setting of volume expansion or pressure overload, the
resulting wall stress initiates synthesis of pre-pro-brain
natriuretic peptide (BNP) in the ventricular myocardium,
although some have questioned the correlation between
individual changes in blood volumes and natriuretic pep-
tide levels. The release of BNP results in improved myo-
cardial relaxation and serves an important regulatory role
in response to acute increases in ventricular volume by
opposing the vasoconstriction, sodium retention, and
antidiuretic effects of the activated renin-angiotensin-
aldosterone system. Natriuretic peptides, both BNP and
n-terminal pro-B-type natriuretic peptide (NT-proBNP),
together with other biochemical and instrumental tests,
can prove useful in assessing diagnosis, severity and
prognosis in patients with acute decompensated HF
(ADHF) [9-16]. Serial measurements of BNP could be
useful not only in guiding the diagnosis of HF, but also in
guiding decisions towards therapy and the evaluation of
HF stabilization [16-18]. There is a large body of evidence
that natriuretic peptides are independent predictors of
total mortality, cardiovascular mortality, and HF hospi-
talizations in both acute and chronic HF [19-23]. In-hos-
pital BNP changes with HF patients appear to be a strong
independent predictor of re-hospitalization and mortality
[23,24]. Moreover, repeated BNP measurements in
patients admitted to the hospital with ADHF could pre-
dict outcomes [24,25], even if serial BNP levels are chal-
lenged by several factors (individual variability,
spontaneous fluctuations) [26,27]. Cheng and colleagues
demonstrated that patients with a significant decrease of
BNP at discharge compared with admission BNP levels
had better outcomes, whereas BNP levels dropped mini-
mally during hospitalization in patients that were re-hos-
pitalized within 30 days [24]. In addition, Cohen-Solal
and colleagues demonstrated that patients with a 30% or
higher BNP value from baseline, at follow-up had
reduced mortality risk compared with those with little or
no BNP decrease [28]. It could be also useful to identify
patients with ADHF who, after admission to the emer-
gency department (ED), evidence of a reduction in BNP
after acute treatment with diuretics or vasodilators. The
aim of our study was to evaluate the role of BNP percent-
age variations at 24 hours and at discharge time com-
pared with its value at admission in the ED in
demonstrating its potential predictive value for future
cardiovascular events (deaths and/or re-hospitalizations).
Materials and methods
A total of 287 consecutive patients (Table 1) admitted to
the ED for ADHF were enrolled from eight I talian ED
centers (Malpighi University Hospital-Bologna; Vittorio
Emanuele Hospital-Catania; S. Martino University Hos-
pital-Genova; Policlinico Federico II University Hospital-
Napoli; Policlinico of Padova University Hospital-Padova;
Ravenna Hospital-Ravenna; S. Andrea Hospital, Univer-
sity La Sapienza-Roma; Policlinico Umberto I, University
La Sapienza-Roma) from January 2006 to November
2007. The diagnosis of ADHF was performed on the basis
of current guidelines [6]. The majority of patients (n =
243) had a ADHF as decompensation of chronic HF and
the remaining patients (n = 44) had an episode of HF of
new diagnosis. Two independent cardiologists reviewed
the patients and confirmed the diagnosis of ADHF at dis-
charge. Exclusion criteria were: acute coronary syn-
dromes including myocardial infarction, body mass index
of 30 Kg/m2 or higher, renal failure maintained on hemo-
dialysis, or dyspnea due to trauma or other causes. The
study conformed to the Helsinki declaration and the
study protocol was approved by the local ethical commit-
tees of all participating hospitals. Written informed con-
sent for the study was obtained from each patient before
Table 1: Patient characteristics
Number of patients 247
Age in years (mean ± SD) 76 ± 12
Sex
Male 118
Female 129
NYHA functional classification
III 33%
IV 67%
Heart rate beats/minute (mean ± SD) 91 ± 22
Systolic blood pressure mmHg (mean ± SD) 143 ± 29
Diastolic blood pressure mmHg (mean ± SD) 79 ± 16
Respiratory rate breaths/minute (mean ± SD) 25 ± 7
Oxygen saturation %(mean ± SD) 91 ± 6
Ejection fraction %(mean ± SD) 45 ± 13
<50% 59%
>50% 41%
Past medical history %
Hypertension 70%
Coronary heart disease 45%
Diabetes mellitus 29%
Atrial fibrillation 44%
NYHA, New York Heart Association; SD, standard deviation.Di Somma et al. Critical Care 2010, 14:R116
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entering the study. Documentation of the personal medi-
cal history was obtained. Each patient underwent physi-
cal examination, electrocardiogram, chest x-ray, arterial
blood gas analysis, an echocardiographic exam was
optional but the majority of patients (n = 249) underwent
an echocardiographic exam at admission with, at least,
the evaluation of ejection fraction. Blood tests for hemo-
chromocytometric exam, creatinine, urea, electrolytes,
and cardiac enzymes were performed. Test results and
therapy were reported by the ED in a case report and the
ED physicians were asked to rate the severity of HF by
New York Heart Association (NYHA) classification. All
data were collected in system software by the coordinat-
ing center. Each patient was treated with a standard dos-
age of nitrates, beta-blockers, angiotensin-converting
enzyme (ACE) inhibitors and diuretics accordingly to
guidelines for ADHF and assessed by physical exam at
admission [6]. Therapy was accurately recorded during
the course of hospitalization. All patients enrolled had a
venous blood sample collected in an EDTA tube to mea-
sure BNP levels at admission in the ED and repeated at 24
hours, and at the time of discharge. BNP measurement
was tested in Triage®-BNP test device (Biosite-Inverness
Medical, San Diego, CA, USA), a single-use fluorescence
immunoassay 'ready to use' following the manufacturers
recommendations for point-of-care testing. The follow-
ing concomitant clinical and laboratory parameters were
considered for discharge criteria: reduction of dyspnoea,
respiratory rate below 30 breaths/min, oxygen saturation
above 90%, complete clearance of rales at chest examina-
tion, and significant reduction of lower limb edema [18].
Fourty patients were moved from EDs to other hospitals,
and their BNP discharge samples were lost, so they were
excluded from the statistical analysis. The statistical anal-
ysis was performed on 247 patients. Patients' follow-up
was performed at 30, 90 and 180 days following discharge
from ED. In the 247 remaining patients, follow-up was
performed by telephone interviews or visits to outpatient
clinic and patients or other family components were
asked to clarify if the patients had other re-hospitaliza-
tions for dyspnoea or edema or deaths for cardiovascular
events. On the basis of the BNP absolute value at the
moment of discharge, patients were divided into two pre-
specified groups of more than 300 pg/ml or less than 300
pg/ml according to literature data [29-31]. The patients
were followed to define the odds ratio (OR) to evaluate
what incidence of adverse events occurred in the two
groups. Numerical values are presented as medians with
interquartile ranges (IQR), as appropriate. Categorical
values are presented as numbers and percentages.
Receiver-operating characteristic (ROC) curves were cre-
ated to identify the prognostic value of a drop in percent-
age of BNP level at 24 hours after hospitalization and a
drop in percentage of BNP level at discharge. Optimal
cut-off points were defined by maximization the product
of sensitivity and specificity. Univariate logistic regres-
sion analysis was used to estimate ORs for the various
subgroups created. Multivariate logistic regression was
utilized to test for the significance of the two BNP indica-
tors (discharge and percentage change) simultaneously
and to test for the interaction of these two predictors. For
all comparisons, a P value less than 0.05 was considered
statistically significant. All statistics were calculated with
Statistical Package for Social Sciences version 12.0 for
Windows (SPSS Inc., Chicago, IL, USA).
Results
The characteristics of studied patients are presented in
Table 1. The following drugs were administered during
hospitalization: intravenous loop diuretics to all patients
(furosemide); beta-blockers to 22.4%, ACE inhibitors to
51.0%; angiotensin II receptor blockers, (accordingly to
ADHF guidelines) in all centres [6], and digoxin and
spironolactone in selected cases; and oxygen delivery to
maintain oxygen saturation in more than 90% or patients.
Continuous positive air-way pressure was utilized for 12%
of the patients. The sample was quite homogeneous
across the eight centers. In fact the number of patients in
NYHA class III and IV was similar at ED admission.
Moreover, also the BNP levels at admission in the eight
centers were comparable. The treatment in all centers
was quite similar. In fact, comparing BNP percentage
decreases at 24 hours and discharge, there was no signifi-
cant difference among centers. In all study subjects (247
patients) BNP median (IQR) value at admission was 822
(412 to 1390) pg/mL, at 24 hours it was 593 (270 to 1953)
pg/mL and at discharge it was 325 (160 to 725) pg/mL.
During follow up, there were 78 patients with events
among the 247 patients enrolled in the study: seven
deaths (one due to a noncardiac cause and six deaths due
to ADHF) and 71 hospitalizations for dyspnoea and/or
relapse congestion between discharge and 180 days. Table
2 shows the distribution of cardiovascular events at vari-
ous times of follow-up. The OR for those with a discharge
BNP of 300 pg/ml or higher as compared with those
below this value was 3.17 (95% CI 1.79-5.60, p < 0.001).
Figure 1 shows receiver operating characteristics
(ROC) curves for drop percentage of BNP level at 24
hours after hospitalization and for drop percentage of
BNP level at discharge. Their AUC are respectively 0.646
and 0.704 (p < 0.001 in both cases). The odds ratio for
those with a BNP decrease of <46% (statistically deter-
mined by ROC curve) at discharge compared to those
with a decrease of at least 46% was 6.18 (95% confidence
interval (CI) 3.49 to 10.97, P  < 0.001). In multivariate
analysis including both predictors and their interaction,
the interaction term was not significant (P = 0.874). For
an analysis including both predictors but no interactionDi Somma et al. Critical Care 2010, 14:R116
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term, the OR for discharge BNP 300 pg/ml or above was
1.93 (95% CI 1.03 to 3.59, P = 0.039) and the OR for per-
centage decline in BNP below 46% was 5.06 (95% CI 2.78
to 9.22, P  < 0.001), indicating that there were additive
effects of both predictors. Taking both predictors
together a four-group model was developed. The OR of
the patients whose BNP level at discharge was above 300
pg/mL and whose percentage decrease at discharge was
above 46% compared with those whose BNP level at dis-
charge was below 300 pg/mL and whose percentage
decrease at discharge was above 46% was 1.83 (Figures 2
and 3). The OR of the patients whose BNP level at dis-
charge was below 300 pg/mL and whose percentage
decrease at discharge was less than 46% compared with
the group whose BNP level at discharge was below 300
pg/mL and whose percentage decrease at discharge was
>46% was 4.75 (p < 0.002) (Figure 2 and 3). The odds ratio
of the patients whose BNP level at discharge was >300 pg/
mL and whose percentage decrease at discharge was
below 46% compared with the group whose BNP level at
discharge was below 300 pg/mL and whose percentage
decrease at discharge was above 46% was 9.61 (P < 0.001;
Figures 2 and 3).
Discussion
In our previous studies we demonstrated that, in ADHF
patients, the clinical improvement evaluated by clinical
criteria as reduction in respiratory rate, decrease of limb
edema, and pulmonary rales, is coupled with a progres-
sive reduction of BNP levels obtained at hospital dis-
charge [16-18].
This study also confirms our previous results. In fact, in
our studied population there was a significant mean
decrease of BNP levels at discharge time compared with
ED admission.
Making the decision to discharge a patient admitted to
hospital for ADHF represents one of the major problems
for ED physicians. The decision to discharge a patient is
generally based on the clinician's subjective perception of
the patient's condition, and thus, readmission rates to the
hospital (44% at 180 days) and their associated costs are
extremely high [32]. The lack of objective parameters to
evaluate achieved clinical stability may lead to two conse-
quences: patients who require more intensive treatment
and in-hospital monitoring may be inadvertently dis-
charged or patients may be discharged on inadequate
therapeutic regimens. On the contrary, those who could
be quickly and safely discharged undergo an unjustifiable
long stay in the ED. Clinical congestion is often difficult
to assess [33]. A patient's weight changes do not always
Table 2: Events and timing
Time 30 days 90 days 180 days
Re-hospitalizations 28 20 23
Deaths 1 5 1
NYHA, New York Heart Association; SD, standard deviation.
Figure 1 Receiver operator characteristic curve for percentage 
change at 24 hours and discharge. Percentage changes of brain na-
triuretic peptide at discharge have a higher area under the curve (AUC) 
than percentage changes at 24 hours, for predicting adverse events.
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Figure 2 Event rate by discharge BNP. Patients with discharge brain 
natriuretic peptide (BNP) levels above 300 pg/mL had a higher propor-
tion of individuals with adverse events, as compared with patients with 
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help and a chest x-ray alone cannot lead a physician to
safely discharge a patient [34]. Therefore, we need other
complementary tools. Absolute BNP levels can be consid-
ered as a surrogate for wedge pressure. It has been shown
that decreasing BNP levels are correlated with a decrease
in wedge pressure [35]. BNP is rapidly cleared due to the
shorter half-life (20 minutes) than the inactive form of
NT-proBNP. BNP levels have a 'wet' and 'dry' component.
The dry component is related to a euvolemic condition,
whereas the wet BNP level correlates with the acute con-
gestion of the patient [32]. Reaching a low BNP value at
discharge, bringing the patient as close as possible to his
dry BNP level, can reduce the rate of both events and re-
hospitalizations. At least three consecutive measure-
ments of BNP values (admission, discharge, and a few
weeks later) can help to identify HF patients who have a
poor short-term prognosis, as shown recently by Fag-
giano and colleagues [36]. From our results it seems that
at the moment of discharge if the clinical improvement of
the patients obtained through adequate treatment during
hospitalization time is coupled with a BNP reduction of
more than 46% compared with admission value, and the
absolute value of BNP is below 300 pg/ml, patients can
have lower possibilities to have adverse effects in terms of
re-hospitalizations and/or cardiovascular deaths. In our
opinion this seems to be a very innovative result, in fact,
from the literature no data are available on the percentage
reduction of BNP obtained during hospitalization as a
predictive value for future cardiovascular events. The
clinically significant concentration of BNP for prediction
of outcome is uncertain but we decided, based on previ-
ously published articles, to divide our patients in two
groups depending on whether the BNP was greater or
less than 300 pg/ml. So far, only the absolute value of BNP
at discharge time has been evaluated for a predictive
value [29-31], and from our study the value of 300 pg/ml
also justifies the results that patients with an absolute
level of BNP below 300 pg/ml will have fewer outcomes.
From our data it seems that in patients referred to the ED
for ADHF after 24 hours of medications, an early drop in
BNP level (≥ 25%) was associated with clinical improve-
ment and an absolute value of BNP below 300 pg/mL can
allow the patient to be safely discharged from the hospi-
tal. If a patient does not look compensated but he has
decreased his BNP value by more than 25% at 24 hours,
he should undergo one more day of aggressive treatment
and after that, if he reaches clinical stabilization he can, in
all probability, be discharged; if not, he should be fol-
lowed-up very soon by his physician. If after the first day
of aggressive treatment, the patient does not decrease his
BNP level by more than 25%, it is possible to suggest pro-
viding one more day of aggressive treatment. After that, if
the patient's BNP absolute value drops below 300 pg/mL
and this value seems to mirror a clinical improvement, he
can be discharged. If not, other interventions such as
home health, close medical observation or devices such
as pulmonary arterial catheter, implantable cardioverter
defibrillator, and bi-ventricular pacemaker should be
taken into consideration. If the patients whose drop in
BNP level was less than 25% on the first day of treatment,
after an additional day still does not decrease their abso-
lute BNP value to below 300 pg/mL, a pulmonary arterial
catheter should be inserted and/or a therapy with ino-
tropes should be taken into consideration.
Conclusions
In conclusion, we can assess that, for people admitted to
hospital for ADHF, serial measurements of BNP levels
seem to be useful for a better understanding if the
obtained clinical improvement during hospitalization can
be clarified by a value of BNP that predicts future cardio-
vascular events. The optimal times to assess the BNP lev-
els seemed to be at admission, 24 hours after admission
and at patient discharge. A greater than 25% reduction of
BNP levels 24 hours after admission and a 46% or greater
reduction of BNP levels at discharge compared with the
admission, together with a BNP absolute value of less
than 300 pg/mL, demonstrate a strong negative prognos-
tic value for future cardiovascular outcomes.
Discharge BNP values seem to be a very strong predic-
tor of subsequent outcomes in patients admitted for
ADHF and should be used for reducing future cardiovas-
cular events. In any case it must be taken into account
that from our study population the clinical criteria of
improvement (reduction of dyspnoea, respiratory rate
below 30 breaths/min, oxygen saturation above 90%,
complete clearance of rales at chest examination, signifi-
Figure 3 Odds ratios of BNP precentage change subgroups. Pa-
tients whose brain natriuretic peptide (BNP) values did not decrease 
46% and had a discharge BNP value of 300 pg/mL or more had the 
highest odds ratio for adverse events. D/C: discharge.Di Somma et al. Critical Care 2010, 14:R116
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cant reduction of lower limb edema) were the only used
criteria to discharge a patient. But, from our observa-
t i o n a l  s t u d y ,  i t  r e s u l t e d  t h a t  i f  w e  c o u p l e d  c l i n i c a l
improvement and evaluation, at discharge time, of BNP
percentage changes and absolute value we could have
additive information on the prognosis of these patients.
Limitations of the study include that in this study we did
not investigate what should be done for those patients
who failed to achieve the reduction in BNP at discharge.
In the future, more intention to treat studies should be
properly designed to consider new therapeutic strategies
for those non-responsive patients to the traditional treat-
ment in terms of BNP percentage and absolute value
reduction.
Key messages
• In patients with ADHF, serial assessment of BNP at 
admission, 24 hours after admission, and at discharge 
time are useful to confirm clinical improvement 
obtained during hospitalization.
• A reduction of 25% or greater of BNP at 24 hours 
from hospitalization compared with admission levels 
has a strong negative prognostic value for future car-
diovascular events.
• A reduction of 46% or greater of BNP at discharge 
coupled with BNP absolute value below 300 pg/ml 
demonstrate a strong negative prognostic value for 
future cardiovascular events.
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